Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

VeriStrat proves its prognostic capabilities
November 2018
SHARING OPTIONS:

BOULDER, Colo.—Biodesix announced in the third quarter of 2018 that in a study of samples from non-small cell lung cancer patients, the company’s VeriStrat test was found to be a significant predictor of outcomes (independent of ECOG Performance Status categories), patient EGFR mutation status, treatment received and other clinical variables. The study showed that patients who presented with VeriStrat Poor results and better ECOG PS had worse overall survival than patients with VeriStrat Good results and a worse PS. VeriStrat also proved capable of predicting response differences in EGFR mutation-positive patients and EGFR wild-type patients. EGFR mutation-positive patients with a VeriStrat Good result saw improved overall survival compared to VeriStrat Poor patients when treated with a single-agent EGFR-tyrosine kinase inhibitor (EGFR-TKI), which held true when a combination of two EGFR-TKI therapies were administered. VeriStrat Poor patients performed better on the combination regimen than on erlotinib alone.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.